Molecular Partners Ag (MOLN) FCF Margin Growth (3y) (2023 - 2026)
Molecular Partners Ag (MOLN) FCF Margin Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | -1,272.00 |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.54 Bn | 3.93 Bn | -2,228.00 |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.41 Bn | 54.27 Bn | 52.00 Mn | -5,426.00 |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 9,545.00 |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 4,612.00 |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 1,850.00 |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 14,060.00 |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | -3,088.00 |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10,595.00 |
| Dec 31, 2025 | 11.42 Mn |
| Sep 30, 2025 | 24.57 Mn |
| Jun 30, 2025 | -17.23 Mn |
| Mar 31, 2025 | -10,304.00 |
| Dec 31, 2024 | 120.66 Mn |
| Sep 30, 2024 | -147.61 Mn |
| Jun 30, 2024 | -209.17 Bn |
| Mar 31, 2024 | -61,822.00 |
| Dec 31, 2023 | -84,705.00 |